Pruritic Rash and Oral Erosions During Nivolumab Treatment for Melanoma

Main Article Content

Shant Tamazian
Emily Y. Chu
Cory L. Simpson


Autoimmune Blistering Disease, Bullous Pemphigoid, Immunotherapy, Melanoma


Abstract not available.


1. Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018;79(6):1081-1088.

2. Kridin K, Bergman R. Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid. JAMA Dermatol. 2019;155(2):166-171.

3. Wang LL, Moshiri AS, Novoa R, et al. Comparison of C3d immunohistochemical staining to enzyme-linked immunosorbent assay and immunofluorescence for diagnosis of bullous pemphigoid. J Am Acad Dermatol. 2020;83(1):172-178.

4. Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. The Lancet. 2017;389(10079):1630-1638.

5. Apalla Z, Lallas A, Delli F, et al. Management of immune checkpoint inhibitor-induced bullous pemphigoid. J Am Acad Dermatol. 2020.

6. Singer S, Nelson CA, Lian CG, Dewan AK, LeBoeuf NR. Nonbullous pemphigoid secondary to PD-1 inhibition. JAAD Case Reports. 2019;5(10):898-903.